Collaborative Partnerships in Drug Development

Collaborative Partnerships in Drug Development: An Executive Roundtable Discussion
Tuesday, June 26, 2012
1:30–3:30 pm (ET)

Everyone agrees the current drug development paradigm costs too much, takes too long and produces too little. Hear from the leaders of the CRO industry about how they are working with sponsors to drive innovation and efficiency in drug development. Hot topics to be discussed include:

  • Evolution and future of the CRO industry
  • The changing CRO-sponsor relationship
  • Partnerships, risk-sharing and other emerging models
  • Globalization and managing global regulatory risks
  • Tapping into drug discovery and scientific expertise 
  • “Big Data” and the move toward data standards.
  • Governance structures and quality measures.

This session will engage the audience in a lively dialogue and attendees will depart with actionable takeaways to deploy in their outsourcing relationships. 

Submit questions in advance to  Subject: Collaborative Partnerships


Ed Silverman Ed Silverman
Editor, Pharmalot


Paula Brown Stafford Paula Brown Stafford, MPH
President, Clinical Development Quintiles 
 Jeffrey P McMullenJeffrey P McMullen
President and CEO
PharmaNet/i3, an inVentiv Health Company
Douglas J. PeddicordDouglas J. Peddicord, PhD
Executive Director
Association of Clinical Research Organizations
William J. Sharbaugh William J. Sharbaugh, MA,MSc
Chief Operating Officer
PPD, Inc.
Josef von Rickenbach Josef von Rickenbach, MBA
Chairman and CEO
PAREXEL International
John Watson John Watson
Chief Commercial Officer, Corporate Senior Vice President,
and President of Strategic Partnering Covance

© 2017 DIA